How to Prepare for an FDA Inspection: eQMS Audit Readiness Checklist

Request a Demo

Whether the visit is a routine surveillance inspection, a for-cause investigation, or a pre-approval review, the questions an investigator asks are predictable and the records they request are the same records your quality system should already produce on demand. The difference between a smooth inspection and a stack of Form 483 observations usually comes down to readiness, and readiness comes down to how well your electronic quality management system captures, controls, and retrieves evidence. This guide walks through a complete audit readiness checklist and shows where an audit-efficient eQMS built for FDA and ISO removes the scramble entirely.

Why FDA Inspection Readiness Is a Daily Discipline

The most common mistake medical device manufacturers make is treating inspection preparation as an event rather than a state. Teams that only assemble records when they receive notice of an inspection spend days chasing signatures, reconciling spreadsheet versions, and reconstructing timelines from memory. Teams that maintain a continuously audit-efficient quality management platform simply grant an investigator access to controlled records that are already complete. Readiness is not a binder you build in a week. It is the natural output of a quality system where every document, change, complaint, and corrective action is captured in real time with a defensible audit trail.

Investigators are trained to follow the Compliance Program (CP) 7382.850, Inspection of Medical Device Manufacturers, which is structured around six QMS Areas and four Other Applicable FDA Requirements (OAFRs). Because these subsystems are interconnected, a weakness in one area quickly exposes gaps in others. A centralized system that links records across subsystems keeps those connections intact, which is exactly what an integrated eQMS platform for medical devices is designed to do.

The eQMS Audit Readiness Checklist

Work through each area below well before an inspection is scheduled. Every item maps to records an FDA investigator is likely to request.

1. Management Oversight

Confirm your quality policy and quality objectives are current, approved, and communicated across the organization.
Verify management review meetings are documented with attendees, inputs, decisions, and action items, and that the discussion reflects risk-based decision-making rather than performance metrics alone.
Ensure organizational responsibilities and authority are defined and traceable to trained, qualified personnel.
Confirm every employee is trained on the current revision of the procedures relevant to their role. A training management system links training completion to document revisions so retraining triggers automatically.

2. Design and Development

Ensure the design and development file is complete, with traceability from user needs through inputs, outputs, verification, and validation.
Confirm design changes are controlled and risk assessed. A design control solution preserves this traceability automatically.

3. Change Control

Confirm every change to a design, process, supplier, or software element goes through a documented risk reassessment before it takes effect, not just a log entry after the fact.
Verify change records show what changed, who approved it, and how the resulting risk was reevaluated.
Confirm every controlled document carries the correct revision, approval signatures, and effective date, with obsolete versions removed from circulation. A controlled document management system enforces this automatically.

4. Measurement, Analysis, and Improvement

Review open and closed CAPAs for root cause analysis, effectiveness checks, and closure evidence. Use an automated CAPA workflow so escalations and effectiveness reviews are enforced by the system rather than by memory.
Verify complaints are documented, evaluated for reportability, and linked to any resulting investigation or CAPA. A complaint and nonconformance management platform keeps these records connected.
Confirm internal audit findings are documented factually and specifically, and that they flow into corrective action — FDA can now examine these reports directly.
Confirm nonconforming material dispositions are recorded and justified.

5. Outsourcing and Purchasing

Verify approved supplier lists, supplier evaluations, and incoming inspection records are current. A supplier management system keeps these connected and audit-ready.
Confirm supplier audit reports and purchasing agreements are available on request, since FDA can now review them directly as part of this area.

6. Production and Service Provision

Confirm production and service records reflect the current approved procedures and specifications, with no obsolete versions in circulation.
Verify calibration and maintenance records are up to date with no overdue equipment in use.

Every inspection also evaluates four Other Applicable FDA Requirements (OAFRs) alongside the QMS Areas above.

7. Medical Device Reporting (MDR)

Confirm every complaint includes a documented reportability determination, with the rationale recorded whether or not it was ultimately reportable.

8. Corrections and Removals

Confirm you have a documented process for evaluating whether a correction or removal is required, with any resulting action and required FDA reporting recorded.

9. Tracking

If your device is subject to tracking requirements, confirm tracking records are current, complete, and retrievable on request.

10. Unique Device Identification (UDI)

Confirm UDI labeling and the corresponding GUDID submission data are accurate and current.

During the Inspection: How to Present Records

When the investigator arrives, designate a host, a scribe, and a backroom of personnel able to retrieve records. Answer only the question asked, provide exactly the record requested, and never speculate. A system with fast search and controlled retrieval lets your team produce a specific batch record, CAPA, or training log in seconds rather than leaving an investigator waiting. Every minute of delay invites broader requests. This is where the continuous readiness of a modern platform pays off, and it is why so many manufacturers move away from fragmented spreadsheets toward a single platform for quality, compliance, and risk.

Speed Signals Control

Experienced investigators read something into how quickly you produce records. A team that retrieves a specific complaint file, its linked investigation, and the resulting CAPA within a few minutes signals a quality system that is genuinely in control. A team that disappears for an hour to hunt through shared drives signals the opposite, and it invites the investigator to widen the scope of their request. The goal is not to rehearse answers but to build a system where retrieval is trivial because everything is already connected. When your document control, complaint handling, and corrective action records live in one place with a shared audit trail, producing a complete evidence package is a search, not a project. This is the practical payoff of moving from fragmented tools to a centralized quality data management system, where every record is one query away.

Common Findings You Can Eliminate in Advance

Early data from the first QMSR inspections is starting to arrive, and FDA officials have described where the findings are clustering. The categories are familiar — what changed is the inspection path that gets you there.

Risk management treated as a static design deliverable instead of a living system. This is the most cited QMSR-era finding so far, by a wide margin, according to FDA’s own reporting on early inspections.
CAPA effectiveness checks that are missing or superficial. Use an automated CAPA workflow so effectiveness verification is enforced by the system rather than left to memory.
Complaint handling and feedback that isn’t consistently evaluated for reportability. A complaint and nonconformance management platform keeps these records connected.
Supplier and purchasing controls that lag behind the new scrutiny on outsourcing — FDA can now review supplier audit reports directly. A supplier management system keeps this evidence current.
Internal audit reports that aren’t factual, specific, or followed through to corrective action. These reports no longer have the limited protection from FDA review they once had.

When these categories are handled by the system rather than by memory, the surface area for findings shrinks dramatically. Manufacturers who want this level of control across every subsystem typically standardize on an integrated QMS for end-to-end compliance.

Preparing Your People, Not Just Your Records

Even a flawless record set can be undermined by an unprepared team. Before an inspection, brief everyone who may interact with the investigator on a few simple principles: answer only the question asked, do not volunteer information beyond the request, and never guess. If someone does not know an answer, the correct response is to find the person who does, not to speculate. Designate a single point of contact who manages the flow of requests and a scribe who logs every document provided and every question asked. Keeping your own record of the inspection helps you respond accurately afterward and identify any patterns in what the investigator focused on. Practice this with a mock inspection so the roles feel natural. A team that has rehearsed the logistics can focus its attention on presenting a quality system that already speaks for itself.

After the Inspection: Closing the Loop

If you receive Form 483 observations, your response window is short and your corrective actions must be credible. Tie every observation to a documented CAPA with root cause analysis, a corrective action plan, and an effectiveness check. A system that connects the observation to the resulting action and to the updated procedure gives you a clean, traceable response package. Manufacturers who want to shorten this cycle often adopt an approach built for faster FDA readiness with modern QMS software, where evidence is generated continuously rather than reconstructed under pressure.

Frequently Asked Questions

How much notice does the FDA give before a medical device inspection?

Routine surveillance inspections are often unannounced or come with only a few days of notice, while pre-approval inspections are typically scheduled. Because notice is limited, continuous readiness is the only reliable strategy.

What is the single most common cause of Form 483 observations?

Documentation and CAPA weaknesses dominate. Incomplete records, overdue corrective actions, and uncontrolled documents account for a large share of observations, all of which a well-configured eQMS is designed to prevent.

Can an eQMS guarantee a passed inspection?

No system guarantees an outcome, but a properly implemented eQMS removes the most common causes of findings by enforcing control, traceability, and timely action across every quality subsystem.

Ready to Make Every Inspection a Non-Event

Inspection readiness is a byproduct of a quality system that works every day, not a project you launch when the FDA calls. To see how continuous audit readiness works in practice, talk to an eQMS expert or request a demo.